Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR1313150

— · E

ebd98402-1e1f-5b5f-a28c-4fbde9c8802a

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • G2M_CHECKPOINT+0.400
  • E2F_TARGETS+0.390
  • HEDGEHOG_SIGNALING+0.380
  • MITOTIC_SPINDLE+0.370
  • APICAL_SURFACE+0.330
  • PROTEIN_SECRETION+0.330
  • INFLAMMATORY_RESPONSE+0.300
  • UV_RESPONSE_DN+0.290
  • ALLOGRAFT_REJECTION+0.280
  • APICAL_JUNCTION+0.280

Top 10 suppressed

  • DNA_REPAIR-0.200
  • XENOBIOTIC_METABOLISM-0.190
  • INTERFERON_ALPHA_RESPONSE-0.180
  • MYC_TARGETS_V2-0.170
  • ANGIOGENESIS-0.110
  • BILE_ACID_METABOLISM-0.080
  • FATTY_ACID_METABOLISM-0.030
  • P53_PATHWAY+0.010
  • ESTROGEN_RESPONSE_EARLY+0.040
  • INTERFERON_GAMMA_RESPONSE+0.040

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1EPT0578
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.795
27EDF85E0-24E3-43B6-8C00-BBA39235266E
brain-umap@2
——0.776
3DRR168559
bladder-landscape@3
——0.756
4SRR1313161
breast-umap@18
—C0.752
5TCGA-77-7337-01A-21R-2045-07
lung-landscapes@6
—cohortSQ10.748
6TCGA-E2-A1B0-01A-11R-A12P-07
breast-umap@18
—C0.735
7SJEPD032263_D1.RNA-Seq
medullo-epn-umap@date-based
EPNAnaplastic EPN0.733
820140163.TNBC
breast-umap@18
—D0.733
9TCGA-85-6561-01A-11R-1820-07
lung-landscapes@6
—cohortSQ10.728
10TCGA-A8-A07E-01A-11R-A034-07
breast-umap@18
—A0.727

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 43 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
G2M_CHECKPOINT0.400Inavolisib— uncovered
E2F_TARGETS0.390Inavolisib— uncovered
HEDGEHOG_SIGNALING0.380Inavolisib— uncovered
MITOTIC_SPINDLE0.370Inavolisib— uncovered
APICAL_SURFACE0.330Temsirolimus— uncovered
PROTEIN_SECRETION0.330Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.300Idelalisib— uncovered
UV_RESPONSE_DN0.290Inavolisib— uncovered
ALLOGRAFT_REJECTION0.280Idelalisib— uncovered
APICAL_JUNCTION0.280Inavolisib— uncovered
NOTCH_SIGNALING0.280Inavolisib— uncovered
PANCREAS_BETA_CELLS0.280Cobimetinib— uncovered
ANDROGEN_RESPONSE0.270Inavolisib— uncovered
MYC_TARGETS_V10.270Inavolisib— uncovered
TGF_BETA_SIGNALING0.260Inavolisib— uncovered
COMPLEMENT0.250Inavolisib— uncovered
MTORC1_SIGNALING0.240Inavolisib— uncovered
HEME_METABOLISM0.230Temsirolimus— uncovered
COAGULATION0.220Binimetinib— uncovered
IL6_JAK_STAT3_SIGNALING0.220Inavolisib— uncovered